GSK starts final-stage tests on severe asthma drug
LONDON (Reuters) - GlaxoSmithKline has started final-stage testing of an experimental drug for treating severe asthma, Britain's biggest drugmaker said on Monday.
The move to progress the injectable antibody treatment mepolizumab into Phase III trials had been expected after an earlier study showed it nearly halved the number of attacks suffered by patients.
Severe refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs.
(Reporting by Ben Hirschler)
- U.S.'s Kerry expresses regret to India over diplomat case |
- Mega Millions winners in Georgia, California to split $648 million |
- China confirms near miss with U.S. ship in South China Sea
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- Fed cuts bond buying in first step away from historic stimulus |
During Soviet times, Sochi gained a reputation for tolerance but the city's once vibrant gay scene has been shrinking as Russia prepares to host the 2014 Winter Games. Slideshow